Upgrades - UBS upgraded UiPath (PATH) to Neutral from Sell with a price target of $17, up from $10, citing that near-term GenAI risk fears appear "overdone" [2] - Needham upgraded TransMedics (TMDX) to Buy from Hold with a price target of $148, indicating that U.S. sales are likely to beat consensus in Q3 according to their transplant tracker [2] - Deutsche Bank upgraded CME Group (CME) to Buy from Hold with a price target of $300, up from $266, believing that organic growth initiatives will drive earnings growth into the high single digits by 2026 [3] - Roth Capital upgraded Core Scientific (CORZ) to Buy from Neutral with a price target of $23.50, up from $17, assuming that the takeover by CoreWeave (CRWV) will not go through [4] - JPMorgan upgraded LendingClub (LC) to Overweight from Neutral with a price target of $22, up from $17, noting that the company has "more ways than ever" to grow originations and profits [5] Downgrades - Mizuho downgraded Enphase Energy (ENPH) to Neutral from Outperform with a price target of $37, down from $50, due to reduced residential solar demand and lower market share [6] - Mizuho downgraded Hologic (HOLX) to Neutral from Outperform with a price target of $78 after the company agreed to be acquired in a transaction valued at up to $79 per share [6] - Wells Fargo downgraded Tegna (TGNA) to Equal Weight from Overweight with an unchanged price target of $22, citing the pending Nexstar (NXST) acquisition [6] - H.C. Wainwright downgraded Avadel Pharmaceuticals (AVDL) to Neutral from Buy with a price target of $20, down from $36, following a definitive agreement to be acquired by Alkermes (ALKS) [6] - Citi downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy with a price target of $12, down from $49, due to disappointing results from the ARCT-032 Phase 2 trial [6]

Core Viewpoint - Class Action Attorney Juan Monteverde and his firm, Monteverde & Associates PC, are investigating Hologic, Inc. regarding its proposed sale to funds managed by Blackstone and TPG, which involves a cash payment of $76.00 per share and a contingent value right of up to $3.00 per share [1] Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2] Transaction Details - Under the proposed transaction, Hologic shareholders will receive $76.00 in cash per share, along with a non-tradeable contingent value right that could yield up to $3.00 per share in two payments of $1.50 each [1]

Core Viewpoint - Hologic, Inc. is undergoing a proposed sale to Blackstone and TPG, valued at up to $18.3 billion, which has led to a downgrade of its stock rating by William Blair from "Outperform" to "Market Perform" [1][2][6] Company Overview - Hologic, Inc. specializes in medical diagnostics and devices within the women's health sector [1] - The company is currently trading at $74.16, reflecting a 3.18% increase from the previous day [4] - Hologic's stock has fluctuated between a high of $84.39 and a low of $51.90 over the past year, with a market capitalization of approximately $16.49 billion [4][6] Acquisition Details - The proposed acquisition involves purchasing all outstanding shares of Hologic at $76 per share, with potential additional payments through a non-tradable contingent value right [2][3] - The deal offers Hologic shareholders a total of $76.00 per share in cash, plus up to $3.00 more through contingent value rights [2] Market Activity - Today's trading volume for Hologic is notably high at 13.85 million shares, indicating strong investor interest amid ongoing acquisition discussions [5][6]

Group 1 - Hologic shareholders will receive $76 per share in cash plus a contingent value right of up to $3 per share, with payments contingent on achieving revenue goals for the Breast Health business in fiscal years 2026 and 2027 [2] - The transaction agreement imposes significant penalties on Hologic for accepting competing bids, raising concerns about the board's fiduciary duties to shareholders [3] - The Ademi Firm is investigating potential breaches of fiduciary duty by Hologic's board in relation to the transaction with Blackstone and TPG [1][3]

Core Insights - Hologic (HOLX) and Idexx Laboratories (IDXX) are both considered by investors interested in Medical - Instruments stocks, with a focus on determining which stock is more attractive to value investors [1] Valuation Metrics - Both HOLX and IDXX currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - HOLX has a forward P/E ratio of 16.05, while IDXX has a significantly higher forward P/E of 51.02 [5] - The PEG ratio for HOLX is 2.47, compared to IDXX's PEG ratio of 4.17, suggesting that HOLX may be undervalued relative to its expected earnings growth [5] - HOLX's P/B ratio is 3.3, while IDXX's P/B ratio is 35.29, further indicating that HOLX is more attractively valued [6] - Based on these valuation metrics, HOLX receives a Value grade of B, whereas IDXX receives a Value grade of D, suggesting that HOLX is the superior value option at this time [6]

Core Viewpoint - Hologic has agreed to be acquired by Blackstone and TPG in a take-private deal valued at up to $18.3 billion, with a cash price of $76 per share and additional contingent value rights based on future revenue goals [1][4]. Group 1: Acquisition Details - The acquisition deal values Hologic at up to $18.3 billion, with Blackstone and TPG offering a cash price of $76 per share [1][4]. - The merger agreement includes a 45-day 'go-shop' period, allowing Hologic to seek other offers [3]. - Analysts suggest that bids would need to be in the high $70s to low $80s for a deal to be successful, indicating potential for better investment opportunities elsewhere [3]. Group 2: Market Reaction - Following the announcement, Hologic's stock price increased by more than 3%, reaching $74.26, and is trading above its 50-day and 200-day moving averages [4].

Core Viewpoint - Private equity firms Blackstone and TPG are acquiring Hologic for over $13 billion, taking the company private with a share price of up to $79, representing a 46% premium from late May [1][2]. Deal Structure - The acquisition includes $76 in cash per share, with additional payments contingent on revenue goals from Hologic's breast health business, bringing the total deal value to $18.3 billion when factoring in Hologic's $2.2 billion in cash and short-term investments and $2.5 billion in debt [2]. Regulatory and Approval Status - The deal requires approval from regulators and Hologic shareholders, but has already received unanimous approval from Hologic's board. The transaction is expected to close in the first half of next year [3]. Market Reaction - Following the announcement, Hologic shares increased nearly 4% to $74.62, while broader market indexes showed mixed performance [5]. Post-Transaction Details - After the acquisition, Hologic will be delisted from the Nasdaq stock exchange but will retain its name and headquarters in Marlborough, Massachusetts [5].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Hologic, Inc. to funds managed by Blackstone and TPG for Hologic shareholders [1] Transaction Details - Hologic shareholders are set to receive $76.00 per share in cash [1] - Additionally, shareholders will receive a non-tradable contingent value right to receive up to $3.00 per share, payable in two installments of up to $1.50 each [1]

Core Viewpoint - Blackstone and TPG have agreed to acquire all outstanding shares of a women's health company for $76 per share in cash [1] Company Summary - The acquisition involves a cash payment of $76 for each share of the women's health company [1]

Core Viewpoint - Blackstone and TPG have reached an agreement to acquire Hologic, a medical diagnostics firm, in a deal valued at up to $18.3 billion [1] Company Summary - The acquisition involves two major investment firms, Blackstone and TPG, indicating strong interest in the medical diagnostics sector [1] - Hologic is positioned within the healthcare industry, specifically focusing on medical diagnostics, which is a critical area for investment given the ongoing demand for healthcare solutions [1] Financial Summary - The total deal value for the acquisition of Hologic is up to $18.3 billion, highlighting the significant financial commitment from Blackstone and TPG [1]